VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

Stevo Julius, Sverre E. Kjeldsen, Hans Brunner, Lennart Hansson, Francis Platt, Steffan Ekman, John H. Laragh, Gordon McInnes, Anthony M. Schork, Beverly Smith, Michael Weber, Alberto Zanchetti

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovascular outcomes in 15,314 eligible patients from 31 countries randomized to valsartan or amlodipine-based treatment. Methods: The blood pressure (BP) trends are analyzed in 13,449 of VALUE study patients who had baseline BP and 24 months BP and treatment data. Results: In a cohort of 12,570 patients, baseline 24 and 30 months BP, but not 30 months treatment data, were available. Of 13,449 patients, 92% (N = 12,398) received antihypertensive therapy at baseline. The baseline BP was 153.5/86.9 mm Hg in treated compared to 168.1.8/95.3 mm Hg in 1051 untreated patients. After 6 months both groups had indistinguishable BP values. At 12 months the BP decreased to 141.2/82.9 mm Hg (P <.0001 for systolic BP and diastolic BP versus baseline), at 24 months to 139.1/80 mm Hg (P <.0001 v 12 months), and to 138/79 mm Hg at 30 months (P <.0001 v 24 months). The systolic BP control (<140 mm Hg) at 30 months increased from 21.9% at baseline to 62.2%, the diastolic BP (<90 mm Hg) from 54.2% to 90.2% and the combined control (

Original languageEnglish
Pages (from-to)544-548
Number of pages5
JournalAmerican Journal of Hypertension
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 1 2003

Keywords

  • Amlodipine
  • Blood pressure response to drugs
  • Pulse pressure
  • Valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk'. Together they form a unique fingerprint.

Cite this